José A. Lorente - Concepedia

Author

José A. Lorente

Also Known As

Brendan Sloan, J A Lorente, J Lorente, J. A. Lorente, J. Lorente, J.A. Lorente, JOSE A. LORENTE, JOSÉ A. LORENTE, Jose A Lorente, Jose A. Lorente

186

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario de Getafe Centro de Investigación Biomédica en Red de Enfermedades Respiratorias Universidad Europea Universidad Complutense de Madrid Centro de Investigación Biomédica en Red

About

José A. Lorente is an author at Hospital Universitario de Getafe specializing in medicine, sepsis, and emergency medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	23	1.3K
2	Health Sciences	2	2	33
3	Allergy	1	1	58
4	Anatomy	1	1	13
5	Anesthesia	1	1	28

José A. Lorente

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* Ángel Crespo López, José A. Lorente, Jay S. Steingrub, Critical Care Medicine	2004	917
Sepsis incidence and outcome: Contrasting the intensive care unit with the hospital ward* Fernando Frutos–Vivar, Niall D. Ferguson, Óscar Peñuelas, Critical Care Medicine	2007	360
Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome José A. Lorente, Luis J. Garcia‐Frade, Luis Landín, CHEST Journal Viral SepsisHematologySepsisHemostasisSepsis Phenotyping	1993	314
L-arginine pathway in the sepsis syndrome José A. Lorente, Luis Landín, Raúl de Pablo, Critical Care Medicine	1993	237
Survival Benefit in Critically Ill Burned Patients Receiving Selective Decontamination of the Digestive Tract Miguel A. de la Cal, Enrique Cerdá, P. García-Hierro, Annals of Surgery	2005	193
Effects of blood transfusion on oxygen transport variables in severe sepsis José A. Lorente, Luis Landín, Raúl de Pablo, Critical Care Medicine	1993	152
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial* Steven M. Opal, Pierre‐François Laterre, Edward Abraham, Critical Care Medicine	2004	145
Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)* David I. Watson, Robert F. Grover, Antonio Anzueto, Critical Care Medicine	2004	129
A Randomized and Controlled Trial of the Effect of Treatment Aimed at Maximizing Oxygen Delivery in Patients With Severe Sepsis or Septic Shock Inmaculada Alía, Federico Gordo, José A. Lorente, CHEST Journal Critical Care MedicineSevere SepsisAcute CareSepsisOxygen Therapy	1999	124
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis S. Betty Yan, Benjamin D. Margolis, José A. Lorente, Thrombosis and Haemostasis	2003	121

Page 1